Search

Displaying results 5271 - 5280 of 7540 in total
  1. Drug

    Exametazime

    go.drugbank.com/drugs/DB11179
    Approved

    It acts as a chelating agent for the radioisotope technetium-99m to form a cationic complex.

  2. Drug

    Palmidrol

    go.drugbank.com/drugs/DB14043
    InvestigationalNutraceutical

    A cannabinoid receptor-inactive eCB-related molecule used as prophylactic in helping to prevent respiratory viral infection.

    Categories: Analgesics, Non-NarcoticSynonyms: N-palmitoylethanolamine, N-hexadecanoylethanolamine
  3. Drug

    Methoxyamine

    go.drugbank.com/drugs/DB06328
    Investigational

  4. Drug

    Blonanserin

    go.drugbank.com/drugs/DB09223
    Investigational

    As a second-generation (atypical) antipsychotic, it is significantly more efficacious in the treatment of the negative symptoms of schizophrenia compared to first-generation (typical) antipsychotics.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  5. Drug

    Potassium carbonate

    go.drugbank.com/drugs/DB13977
    Approved

    It presents a large capacity to absorb moisture.

  6. Drug

    Cyclopenthiazide

    go.drugbank.com/drugs/DB13532
    Approved

    In a double blind, randomized crossover study, cyclopenthiazide was effective in reducing diastolic blood pressure in mildly hypertensive non-insulin dependent diabetic patients [A27180].

  7. Drug

    SCB-2019

    go.drugbank.com/drugs/DB15805
    Investigational

    The vaccine was developed and tested by Clover Biopharmaceuticals AUS Pty Ltd.. … As of June 2020, the company is pursuing a randomized, double blind, placebo controlled study (NCT04405908) to test the safety and immunogenicity of the vaccine.

  8. Drug

    Iroxanadine

    go.drugbank.com/drugs/DB05444
    Experimental

    BRX-235 (iroxanadine) is a a novel small molecule synthesized by Biorex, Hungary that acts as a cardioprotective agent. … BRX-235 also causes translocation of calcium-dependent protein kinase C isoform to membranes.

  9. Drug

    Brilaroxazine

    go.drugbank.com/drugs/DB09226
    Investigational

    Brilaroxazine (RP5063) is an investigational atypical antipsychotic which is under development by Reviva Pharmaceuticals for the treatment of schizophrenia and schizoaffective disorder. … Reviva Pharmaceuticals also intends to investigate RP5063 for the treatment of bipolar disorder, major depressive disorder, psychosis/agitation associated with Alzheimer's disease, Parkinson's disease

  10. Drug

    Pipequaline

    go.drugbank.com/drugs/DB13991
    Experimental

    It presents a unique chemical structure that does not follow the structural properties of other drugs of its class. … Due to these differences, this drug is classified as a nonbenzodiazepine anxiolytic.